Population-based colorectal cancer screening: Comparison of two fecal occult blood test

Frontiers in Pharmacology

Volumn 4 JAN, Issue , 2014, Pages

  Zubero, Miren B ^a   Arana Arri, Eunate ^a,b   Pijoan, José I ^a,b,c   Portillo, Isabel ^d   Idigoras, Isabel ^d   López Urrutia, Antonio ^a   Samper, Ana ^e   Uranga, Begoña ^e   Rodríguez, Carmen ^f   Bujanda, Luis ^e,g  

^a HOSPITAL DE CRUCES   (Spain)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d Biodonostia Research Institute ^*  (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

Colorectal cancer; Health impact assessment; Health outcomes research; Immunochemical fecal occult blood test; Population screening

Indexed keywords

GUAIAC;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC EQUIPMENT; FEMALE; HUMAN; INTERMETHOD COMPARISON; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; POPULATION RESEARCH; PRECANCER; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SENSOR;

EID: 84893739468     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00175     Document Type: Article

References (39)

1. Allison, J. E., Sakoda, L. C., Levin, T. R., Tucker, J. P., Tekawa, I. S., Cuff, T., et al. (2007). Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J. Natl. Cancer Inst. 99, 1462-1470. doi: 10.1093/jnci/djm150.
2. Australian Institute of Health and Welfare. (2012). National Bowel Cancer Screening Program Monitoring Report: Phase 2, July 2008-June 2011. Cancer Series NO. 65. Cat. No. CAN 61. Canberra: AIHW. Available at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737421401 (accessed on September 5, 2013.
3. Barros, A. J. D., and Hirakata, V. N. (2003). Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med. Res. Methodol. 3:21. doi: 10.1186/1471-2288-3-21.
4. Bartus, T. (2005). Estimation of marginal effects using margeff. Stata J. 3, 309-329.
5. Castells, A., Mar-Castillejo, M., Mascort, J. J., Amador, F. J., Giraldez, M. D., Andreu, M., et al. (2009). Guía de Práctica Clínica. Prevención del Cáncer Colorrectal. Update 2009. Gastroenterol. Hepatol. 32, 717-758.
6. Castiglione, G., Grazzini, G., Miccinesi, G., Rubeca, T., Sani, C., Turco, P., et al. (2002). Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J. Med. Screen. 9, 99-103. doi: 10.1136/jms.9.3.99.
7. Cole, S. R., Young, G. P., Esterman, A., Cadd, B., and Morcom, J. (2003). A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J. Med. Screen. 10, 117-122. doi: 10.1258/096914103769011003.
8. Department of Health. (2006). English Pilot of Bowel Cancer Screening: An Evaluation of the Second Round. London: Institute of Cancer Research. Available at: http://www.cancerscreening.nhs.uk/bowel/pilot-2nd-round-evaluation.pdf (accessed June 20, 2013).
9. European Code Against Cancer. (2012). European Code Against Cancer, 3rd Version. Available at: http://ec.europa.eu/health-eu/doc/cancercode_en.pdf (accessed June 20, 2013).
10. Faivre, J., Dancourt, V., Denis, B., Dorval, E., Piette, C., Perrin, P., et al. (2012). Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur. J. Cancer 48, 2969-2976. doi: 10.1016/j.ejca.2012.04.007.
11. Fraser, C. G., Mathew, C. M., Mowat, N. A. G., Wilson, A., Carey, F. A., and Steele, R. J. (2006). Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programmeme for colorectal cancer: an observational study. Lancet Oncol. 7, 127-131. doi: 10.1016/S1470-2045(05)70473-3.
12. Guittet, L., Bouvier, V., Mariotte, N., Vallee, J. P., Arsène, D., Boutreux, S., et al. (2007). Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56, 210-214. doi: 10.1136/gut.2006.101428.
13. Hol, L., de Jonge, V., van Leerdam, M. E., van Ballegooijen, M., Looman, C. W., van Vuuren, A. J., et al. (2010). Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur. J. Cancer 46, 2059-2066. doi: 10.1016/j.ejca.2010.03.022.
14. Izarzugaza, M. I., Martínez, R., Audícana, C., Larrañaga, N., Hernández, E., Tobalina, M. C., et al. (2010). El Cáncer en el País Vasco Incidencia, Mortalidad, Supervivencia y Evolución Temporal. Vitoria-Gasteiz: Department of Health of the Basque Government, Servicio Central de Publicaciones del Gobierno Vasco, 126. Available at: http://www.osakidetza.euskadi.net/r85-20319/es/contenidos/informacion/estado_salud/es_5463/adjuntos/cancer.pdf (accessed June 20, 2013).
15. Kahi, C. J., Rex, D. K., and Imperiale, T. F. (2008). Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 135, 380-399. doi: 10.1053/j.gastro.2008.06.026.
16. Karim-Kos, H. E., de Vries, E., Soerjomataram, I., Lemmens, V., Siesling, S., and Coebergh, J. W. (2008). Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur. J. Cancer 44, 1345-1389. doi: 10.1016/j.ejca.2007.12.015.
17. Karsa, L. V., Lignini, T. A., Patnick, J., Lambert, R., and Sauvaget, C. (2010). The dimensions of the CRC problem. Best Pract. Res. Clin. Gastroenterol. 24, 381-396. doi: 10.1016/j.bpg.2010.06.004.
18. Levi, Z., Rozen, P., Hazazi, R., Vilkin, A., Waked, A., Maoz, E., et al. (2007). A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann. Intern. Med. 146, 244-255. doi: 10.7326/0003-4819-146-4-200702200-00003.
19. Málaga López, A., Salas Trejo, D., Sala Felis, T., Ponce Romero, M., Goicoechea Sáez, M., Andrés Martínez, M., et al. (2010). Programa de Cribado de Cáncer Colorrectal de la Comunidad Valenciana. Resultados de la Primera Ronda: 2005-2008. Rev. Esp. Salud Pública 84, 729-741.
20. Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., et al. (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med. 328, 1365-1371. doi: 10.1056/NEJM199305133281901.
21. Ministerio de Sanidad y Política Social. (2010). Estrategia de Cáncer del Sistema Nacional de Salud. Madrid: Centro de publicaciones del Ministerio de Sanidad y Política Social. Available at: http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/pdf/ActualizacionEstrategiaCancer.pdf (accessed June 20, 2013).
22. Moss, S., Ancell-Park, R., and Brenner, H. (2010). "Evaluation and interpretation of screening outcomes," in European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, 1st edn, eds N. Segnan, J. Patnick, and L. von Karsa (Luxembourg: Publications Office of the European Union), 71-102.
23. NHS Purchasing and Supply Agency. (2009). Evaluation Report: Immunochemical Faecal Occult Blood Test. London: Center for Evidence-based Purchasing. Available at: http://www.cancerscreening.nhs.uk/bowel/ifobt.pdf (accessed June 20, 2013).
24. Oono, Y., Iriguchi, Y., Doi, Y., Tomino, Y., Kishi, D., Oda, J., et al. (2010). A retrospective study of immunochemical fecal blood testing for colorectal cancer detection. Clin. Chim. Acta 411, 802-805. doi: 10.1016/j.cca.2010.02.057.
25. Rozen, P., Levi, Z., Hazazi, R., Waked, A., Vilkin, A., Maoz, E., et al. (2009). Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment. Pharmacol. Ther. 29, 450-457. doi: 10.1111/j.1365-2036.2008.03898.x.
26. Rubeca, T., Rapi, S., Confortini, M., Brogioni, M., Grazzini, G., Zappa, M., et al. (2006). Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. Int. J. Biol. Markers 21, 157-161.
27. Scottish Intercollegiate Guidelines Network (SIGN). (2011). Diagnosis and Management of Colorectal Cancer. SIGN Publication No. 126. Edinburgh: SIGN. Available at: http://www.sign.ac.uk/pdf/sign126.pdf (accessed December 2011).
28. Segnan, N., Patnick, J., and von Karsa, L. (eds). (2011). European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. Brussels: European Commission, 386.
29. Shaukat, A., Mongin, S., Geisser, M., Lederle, F. A., Bond, J. H., Mandel, J. S., et al. (2013). Long-term mortality after screening for colorectal cancer. N. Engl. J. Med. 369, 1106-1114. doi: 10.1056/NEJMoa1300720.
30. Smith, A., Young, G., Cole, S., and Bampton, P. (2006). Comparison of a brush sampling fecal immunochemical test for haemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 107, 2152-2159. doi: 10.1002/cncr.22230.
31. UK Colorectal Cancer Screening Pilot Group. (2004). Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 329, 133-137. doi: 10.1136/bmj.38153.491887.7C.
32. Van Roosbroeck, S., Hoeck, S., and Van Hal, G. (2012). Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies. Cancer Epidemiol. 36, e317-e324. doi: 10.1016/j.canep.2012.04.003.
33. Van Rossum, L. G., Van Rijn, A. F., Laheij, R. J., Van Oijen, M. G., Fockens, P., Van Krieken, H. H., et al. (2008). Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135, 82-90. doi: 10.1053/j.gastro.2008.03.040.
34. Van Rossum, L. G. M., van Rijn, A. F., Laheij, R. J. F., van Oijen, M. G., Fockens, P., Jansen, J. B., et al. (2009). Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br. J. Cancer 101, 1274-1281. doi: 10.1038/sj.bjc.6605326.
35. Vilkin, A., Rozen, P., Levi, Z., Waked, A., Maoz, E., Birkenfeld, S., et al. (2005). Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am. J. Gastroenterol. 100, 2519-2525. doi: 10.1111/j.1572-0241.2005.00231.x.
36. Von Euler-Chelpin, M., Brasso, K., and Lynge, E. (2010). Determinants of participation in colorectal cancer screening with faecal occult blood testing. J. Public Health 32, 395-405. doi: 10.1093/pubmed/fdp115.
37. von Karsa, L., Anttila, A., Ronco, G., Ponti, A., Malila, N., Arbyn, M., et al. (2008). Cancer Screening in the European Union Report on the Implementation of the Council Recommendation on Cancer Screening. First Report. Available at: http://ec.europa.eu/health/ph_determinants/genetics/documents/cancer_ screening.pdf (accessed June 20, 2013).
38. Wilschut, J. A., Hol, L., Dekker, E., Jansen, J. B., Van Leerdam, M. E., Lansdorp-Vogelaar, I., et al. (2011). Cost-effectiveness analysis of quantitative immunochemical test for colorectal cancer screening. Gastroenterology 141, 1648-1655. doi: 10.1053/j.gastro.2011.07.020.
39. Wong, B. C., Wong, W. M., Cheung, K. I., Tong, T. S., Rozen, P., Young, G. P., et al. (2003). A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment. Pharmacol. Ther. 18, 941-946. doi: 10.1046/j.1365-2036.2003.01783.x.